As ever a reassuring find. I like the double market prediction for canaloplasty in 5 years. If EYE can also double its share of this segment at the same time due to the ease of use of the iTrack SP should go up by 400% in that time. I wonder if the secret RnD might involve subconjunctival stenting. It also is a growth area it would seem. Where is this research taking place, Adelaide or California? With such growth predicted for canaloplasty it would seem that an LCD success would be very much criticised and challenged.
Nova Eye Medical (EYE) News & Analyst Coverage, page-8
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.005(2.63%) |
Mkt cap ! $44.66M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.5¢ | 19.0¢ | $17.33K | 91.24K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 45000 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 29999 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| EYE (ASX) Chart |